The reasons include, that before removal of tumor-draining lymph nodes (TDLN), the activity of anti-PD-1 or anti-PD-L1 monoclonal antibodies could be crucial, since lymph nodes are essential for anti-PD-1 activity, where dendritic cell presentation of tumor antigens to T cells is enhanced [1,78]. The gene discussed is PDCD1; the disease is neoplasm.